Devyser Diagnostics (DVYSR.ST) Stock Price

Devyser Diagnostics Price

OMX·CLOSED
63.40SEK-0.80 (-1.25 %)
Market closed

Over the last 7 years Devyser Diagnostics grew revenue by 26.6% annually, reaching 250.50 M SEK. For Devyser Diagnostics, the net margin of -3.4% is up versus -22.2% a few years ago. The consensus 12-month price target for Devyser Diagnostics is 168.30 SEK, about 165.5% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 7% above its 52-week low.

Devyser Diagnostics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Devyser Diagnostics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Devyser Diagnostics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Devyser Diagnostics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Devyser Diagnostics Stock Price History
DateDevyser Diagnostics Price
8/14/202663.40 SEK
8/13/202664.20 SEK
8/12/202662.00 SEK
8/11/202662.60 SEK
8/10/202663.60 SEK
8/7/202665.50 SEK
8/6/202665.60 SEK
8/5/202663.60 SEK
8/4/202665.90 SEK
7/31/202666.10 SEK
7/30/202669.60 SEK
7/29/202668.60 SEK
7/28/202664.10 SEK
7/27/202663.50 SEK
7/24/202662.20 SEK
7/23/202662.80 SEK
7/22/202665.30 SEK
7/21/202662.40 SEK
7/20/202663.00 SEK
7/17/202662.30 SEK
7/16/202663.10 SEK
7/15/202661.80 SEK
7/14/202661.60 SEK
7/13/202661.00 SEK
7/10/202661.80 SEK
7/9/202661.60 SEK
7/8/202661.50 SEK
7/7/202659.80 SEK
7/6/202659.20 SEK
7/3/202659.50 SEK
7/2/202682.90 SEK
7/1/202683.50 SEK
6/30/202685.80 SEK
6/29/202685.90 SEK
6/26/202685.00 SEK
6/25/202686.50 SEK
6/24/202685.00 SEK
6/23/202684.90 SEK
6/22/202685.90 SEK
6/18/202686.70 SEK
6/17/202689.20 SEK
6/16/202689.80 SEK
6/15/202689.70 SEK
6/12/202689.70 SEK
6/11/202690.40 SEK
6/10/202692.50 SEK
6/9/202694.60 SEK
6/8/202690.00 SEK
6/5/202692.20 SEK
6/4/202695.40 SEK
6/3/202695.20 SEK
6/2/202692.00 SEK
6/1/202692.80 SEK
5/29/202693.00 SEK
5/28/202693.10 SEK
5/27/202694.00 SEK
5/26/202697.40 SEK
5/25/202699.70 SEK
5/22/202696.50 SEK
5/21/202695.00 SEK
5/20/202693.00 SEK
5/19/202689.50 SEK
5/18/202690.10 SEK
5/15/202689.90 SEK
5/13/202691.00 SEK
5/12/202692.50 SEK
5/11/202694.50 SEK
5/8/202697.10 SEK
5/7/202697.60 SEK
5/6/202697.60 SEK
5/5/202693.80 SEK
5/4/202689.10 SEK
4/30/202694.00 SEK
4/29/202694.90 SEK
4/28/202693.20 SEK
4/27/202695.90 SEK
4/24/202689.50 SEK
4/23/202688.00 SEK
4/22/202688.40 SEK
4/21/202687.30 SEK
4/20/202686.90 SEK
4/17/202685.90 SEK
4/16/202678.80 SEK
4/15/202677.70 SEK
4/14/202678.20 SEK
4/13/202675.50 SEK
4/10/202676.00 SEK
4/9/202676.40 SEK
4/8/202676.80 SEK
4/7/202674.40 SEK
4/2/202677.30 SEK
4/1/202678.60 SEK
3/31/202675.70 SEK
3/30/202676.40 SEK
3/27/202675.90 SEK
3/26/202677.60 SEK
3/25/202677.80 SEK
3/24/202676.00 SEK
3/23/202677.80 SEK
3/20/202677.00 SEK
3/19/202679.80 SEK
3/18/202679.20 SEK
3/17/202679.60 SEK
3/16/202678.40 SEK
3/13/202680.30 SEK
3/12/202684.70 SEK
3/11/202686.40 SEK
3/10/202686.60 SEK
3/9/202686.00 SEK
3/6/202688.90 SEK
3/5/202687.30 SEK
3/4/202690.00 SEK
3/3/202687.50 SEK
3/2/202689.40 SEK
2/27/202690.20 SEK
2/26/202691.30 SEK
2/25/202693.40 SEK
2/24/202691.50 SEK
2/23/202695.10 SEK
2/20/202695.40 SEK
2/19/202696.40 SEK
2/18/202698.50 SEK
2/17/202698.10 SEK
2/16/2026100.00 SEK
2/13/2026102.60 SEK
2/12/2026105.40 SEK
2/11/2026101.80 SEK
2/10/2026107.00 SEK
2/9/2026109.00 SEK
2/6/2026108.40 SEK
2/5/2026106.60 SEK
2/4/2026106.20 SEK
2/3/2026105.80 SEK
2/2/2026106.60 SEK
1/30/2026104.00 SEK
1/29/2026103.00 SEK
1/28/2026104.40 SEK
1/27/2026102.40 SEK
1/26/2026103.40 SEK
1/23/2026106.20 SEK
1/22/2026103.00 SEK
1/21/2026104.00 SEK
1/20/2026104.40 SEK
1/19/2026105.00 SEK
1/16/2026107.60 SEK
1/15/2026110.00 SEK
1/14/2026106.60 SEK
1/13/2026106.00 SEK
1/12/2026109.20 SEK
1/9/2026109.60 SEK
1/8/2026108.60 SEK
1/7/2026110.00 SEK
1/5/2026110.60 SEK
1/2/2026113.60 SEK
12/30/2025114.20 SEK
12/29/2025114.40 SEK
12/23/2025113.80 SEK
12/22/2025111.60 SEK
12/19/2025113.80 SEK
12/18/2025111.00 SEK
12/17/2025110.00 SEK
12/16/2025112.40 SEK
12/15/2025112.60 SEK
12/12/2025120.00 SEK
12/11/2025111.00 SEK
12/10/2025110.00 SEK
12/9/2025104.80 SEK
12/8/2025105.00 SEK
12/5/2025108.20 SEK
12/4/2025108.00 SEK
12/3/2025108.80 SEK
12/2/2025111.60 SEK
12/1/2025112.80 SEK
11/28/2025113.40 SEK
11/27/2025107.00 SEK
11/26/2025108.80 SEK
11/25/2025113.40 SEK
11/24/2025111.00 SEK
11/21/2025109.00 SEK
11/20/2025108.40 SEK
11/19/2025105.00 SEK
11/18/2025109.00 SEK
11/17/2025110.00 SEK
11/14/2025113.60 SEK
11/13/2025113.20 SEK
11/12/2025113.60 SEK
11/11/2025114.00 SEK
11/10/2025111.20 SEK
11/7/2025108.00 SEK
11/6/2025115.00 SEK
11/5/2025111.80 SEK
11/4/2025124.00 SEK
11/3/2025123.00 SEK
10/31/2025129.80 SEK
10/30/2025132.00 SEK
10/29/2025132.40 SEK
10/28/2025135.40 SEK
10/27/2025138.60 SEK
10/24/2025135.20 SEK
10/23/2025136.20 SEK
10/22/2025137.60 SEK
10/21/2025140.20 SEK
10/20/2025136.20 SEK
10/17/2025134.60 SEK
10/16/2025134.60 SEK
10/15/2025134.40 SEK
10/14/2025136.60 SEK
10/13/2025133.60 SEK
10/10/2025137.20 SEK
10/9/2025139.40 SEK
10/8/2025138.00 SEK
10/7/2025140.40 SEK
10/6/2025142.00 SEK
10/3/2025141.60 SEK
10/2/2025140.00 SEK
10/1/2025138.00 SEK
9/30/2025141.80 SEK
9/29/2025140.40 SEK
9/26/2025141.00 SEK
9/25/2025139.40 SEK
9/24/2025145.20 SEK
9/23/2025157.00 SEK
9/22/2025154.60 SEK
9/19/2025157.00 SEK
9/18/2025157.80 SEK
9/17/2025152.80 SEK
9/16/2025149.80 SEK
9/15/2025150.40 SEK
9/12/2025148.40 SEK
9/11/2025149.80 SEK
9/10/2025145.20 SEK
9/9/2025145.00 SEK
9/8/2025145.00 SEK
9/5/2025148.40 SEK
9/4/2025149.60 SEK
9/3/2025156.00 SEK
9/2/2025151.60 SEK
9/1/2025151.60 SEK
8/29/2025151.80 SEK
8/28/2025152.20 SEK
8/27/2025150.00 SEK
8/26/2025147.20 SEK
8/25/2025147.40 SEK
8/22/2025148.80 SEK
8/21/2025147.80 SEK
8/20/2025145.40 SEK
8/19/2025145.40 SEK
8/18/2025146.20 SEK
Access this data via the Eulerpool API
Get Free API Key

Devyser Diagnostics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
93.48 M SEK
-21.56 M SEK
-20.73 M SEK
Jan 1, 2022
126.61 M SEK
-54.95 M SEK
-45.95 M SEK
Jan 1, 2023
169.30 M SEK
-56.50 M SEK
-53.60 M SEK
Jan 1, 2024
216.90 M SEK
-58.30 M SEK
-61.50 M SEK
Jan 1, 2025
250.50 M SEK
10.60 M SEK
-8.40 M SEK
Jan 1, 2026 (e)
265.87 M SEK
-62.93 M SEK
21.20 M SEK
Jan 1, 2027 (e)
326.77 M SEK
-77.35 M SEK
50.73 M SEK
Jan 1, 2028 (e)
393.73 M SEK
-93.20 M SEK
86.58 M SEK

Devyser Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 11:49 PM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
201820192020202120222023202420252026e2027e2028e
48.0064.0065.0093.00126.00169.00216.00250.00265.00326.00393.00
–33.331.5643.0835.4834.1327.8115.746.0023.0220.55
70.8381.2586.1579.5783.3387.5779.6380.4080.4080.4080.40
34.0052.0056.0074.00105.00148.00172.00201.00213.06262.10315.97
-3.008.00-6.00-21.00-54.00-56.00-58.0010.00-62.00-77.00-93.00
-6.2512.50-9.23-22.58-42.86-33.14-26.854.00-23.40-23.62-23.66
–7.00-10.00-20.00-45.00-53.00-61.00-8.0021.0050.0086.00
––-242.86100.00125.0017.7815.09-86.89-362.50138.1072.00
16.7016.7016.7011.4316.1216.2816.6216.7016.7016.7016.70
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Devyser Diagnostics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Devyser Diagnostics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Devyser Diagnostics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Devyser Diagnostics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Devyser Diagnostics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Devyser Diagnostics stock margins

The Devyser Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Devyser Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Devyser Diagnostics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
79.87 %
-23.07 %
-22.17 %
Jan 1, 2022
83.54 %
-43.40 %
-36.29 %
Jan 1, 2023
87.48 %
-33.37 %
-31.66 %
Jan 1, 2024
79.62 %
-26.88 %
-28.35 %
Jan 1, 2025
80.60 %
4.23 %
-3.35 %
Jan 1, 2026 (e)
80.60 %
-23.67 %
7.97 %
Jan 1, 2027 (e)
80.60 %
-23.67 %
15.52 %
Jan 1, 2028 (e)
80.60 %
-23.67 %
21.99 %

Devyser Diagnostics Stock Revenue, EBIT, Earnings per Share

The Devyser Diagnostics earnings per share therefore indicates how much revenue Devyser Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
8.18 SEK
-1.89 SEK
-1.81 SEK
Jan 1, 2022
7.85 SEK
-3.41 SEK
-2.85 SEK
Jan 1, 2023
10.40 SEK
-3.47 SEK
-3.29 SEK
Jan 1, 2024
13.05 SEK
-3.51 SEK
-3.70 SEK
Jan 1, 2025
15.00 SEK
0.63 SEK
-0.50 SEK
Jan 1, 2026 (e)
15.97 SEK
-3.77 SEK
1.27 SEK
Jan 1, 2027 (e)
19.63 SEK
-4.63 SEK
3.05 SEK
Jan 1, 2028 (e)
23.65 SEK
-5.58 SEK
5.20 SEK

Devyser Diagnostics business model & stock analysis

Devyser Diagnostics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Devyser Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio

Devyser Diagnostics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Devyser Diagnostics shares outstanding

The number of shares of Devyser Diagnostics was 16.7 M in 2025. This indicates how many shares Devyser Diagnostics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
11.43 M Stocks
Jan 1, 2022
16.12 M Stocks
Jan 1, 2023
16.28 M Stocks
Jan 1, 2024
16.62 M Stocks
Jan 1, 2025
16.70 M Stocks
Jan 1, 2026 (e)
16.70 M Stocks
Jan 1, 2027 (e)
16.70 M Stocks
Jan 1, 2028 (e)
16.70 M Stocks

Current Devyser Diagnostics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.60 %
Buy
90.91 % (10)
Hold
9.09 % (1)
Sell
0.00 % (0)
12M Price Target
168.30
Last Price
63.40
Currency
SEK
12M Return Potential
165.46 %
LTM Return
0 %

Devyser Diagnostics shareholder structure

% Name
5.93514%
Premier Asset Management Ltd
Premier Asset Management Ltd
3.00300%
Deka Investment GmbH
Deka Investment GmbH
2.40240%
Handelsbanken Kapitalförvaltning AB
Handelsbanken Kapitalförvaltning AB
2.07759%
Healthinvest Partners AB
Healthinvest Partners AB
1.16462%
Polar Capital LLP
Polar Capital LLP
1.14114%
Carnegie Fonder AB
Carnegie Fonder AB

Devyser Diagnostics Beneficial Ownership Filings (SEC 13D/G)

Free Float
41.9%
Float Shares
-
Shares Outstanding
-

Devyser Diagnostics Executives and Management Board

13 members · avg. age 51 · 38 % women

Management

JW

Mr. Jan Wahlstroem

Chief Executive Officer

–
SB

Ms. Sabina Berlin (40)

Chief Financial Officer

–
GR

Mr. Goran Rydin (54)

Chief Operating Officer

–
CW

Ms. Camilla Wiberg (44)

Chief Human Resources Officer

–
MU

Mr. Michael Uhlin

Chief Scientific Officer

–
TK

Mr. Theis Kipling (41)

Chief Commercial Officer

–

Board of Directors

MA

Ms. Mia Arnhult (56)

Chairman of the Board

279,000.00 SEK
FD

Mr. Fredrik Dahl (48)

Director · since 2021

144,000.00 SEK
PG

Ms. Pia Gideon (69)

Independent Director

134,000.00 SEK
FM

Mr. Fredrik Mattsson (51)

Independent Director

82,000.00 SEK
ID

Ms. Isabelle Ducellier (56)

Director

–
OE

Mr. Olof Ericsson (47)

Director

–

Frequently asked questions about Devyser Diagnostics

Analysts currently set an average price target of 168.30 SEK for the Devyser Diagnostics stock (median: 168.30 SEK), implying +165.5 % versus the latest price. The consensus is based on 11 analyst ratings.

Devyser Diagnostics Analyst Price Targets 2026

11 analysts currently rate the Devyser Diagnostics stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Devyser Diagnostics to generate revenue of 265.87 M SEK and earnings per share of 1.27 SEK.

Devyser Diagnostics Analyst Price Targets 2026

Converted at the current exchange rate, the Devyser Diagnostics share trades at 5.76 EUR (63.40 SEK).

The Devyser Diagnostics share (DVYSR.ST) is listed on 3 stock exchanges, including: Frankfurt (OL0.F), München (OL0.MU).

No history available for Devyser Diagnostics.

The expected revenue of Devyser Diagnostics is 265.87 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Devyser Diagnostics is 21.20 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Devyser Diagnostics is currently 49.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Devyser Diagnostics stock.

The price-to-sales ratio (P/S) of Devyser Diagnostics is currently 3.98. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Devyser Diagnostics stock.

The Eulerpool Quality Score for Devyser Diagnostics is 3/10.

The ISIN of Devyser Diagnostics is SE0016588867. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Devyser Diagnostics is A3C811. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Devyser Diagnostics is DVYSR.ST. The ticker symbol is used to trade Devyser Diagnostics shares on the stock exchange.

Devyser Diagnostics paid dividends every year for the past 0 years.

Devyser Diagnostics is assigned to the 'Health' sector.

The dividends of Devyser Diagnostics are distributed in SEK.

All fundamentals and in-depth analysis of Devyser Diagnostics

Our stock analysis for Devyser Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Devyser Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Devyser Diagnostics Stock
Devyser Diagnostics Revenue→
Devyser Diagnostics Stock
Devyser Diagnostics Net Income→
Devyser Diagnostics Stock
Devyser Diagnostics P/E→
Devyser Diagnostics Stock
Devyser Diagnostics P/S→
Devyser Diagnostics Stock
Devyser Diagnostics EBIT→
Devyser Diagnostics Stock
Devyser Diagnostics Dividend→
Devyser Diagnostics Stock
Devyser Diagnostics Directors Dealings→
Devyser Diagnostics Stock
Devyser Diagnostics Stocks→
Devyser Diagnostics Stock
Devyser Diagnostics Market capitalization→
Devyser Diagnostics Stock
Devyser Diagnostics Debt→
Devyser Diagnostics Stock
Devyser Diagnostics Liabilities→
Devyser Diagnostics Stock
Devyser Diagnostics Equity→
Devyser Diagnostics Stock
Devyser Diagnostics AAQS→
Devyser Diagnostics Stock
Devyser Diagnostics Employees→
Devyser Diagnostics Stock
Devyser Diagnostics ROE→
Devyser Diagnostics Stock
Devyser Diagnostics ROA→
Devyser Diagnostics Stock
Devyser Diagnostics ROCE→
Devyser Diagnostics Stock
Devyser Diagnostics News→
Devyser Diagnostics Stock
Devyser Diagnostics Analyst Price Targets→

Health Stocks

DexcomDevonian Health GroupDextech MedicalDesign TherapeuticsDezhan Healthcare CoDermata TherapeuticsDhanvantri Jeevan RekhaDermapharm HoldingDhg Pharmaceutical Joint-StockDENTSPLY SIRONADhruv WellnessDentium CoAll Stocks A–Z →